ESMO 2019: Results from the TRAXAR study to assess TRC105 plus axitinib for metastatic kidney cancer

Results from the TRAXAR clinical trial to assess TRC105 plus axitinib in pre-treated patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology¬†(ESMO) conference in Barcelona over the weekend. Endoglin is an endothelial cell surface receptor that has a role in the development and growth of blood vessels (angiogenesis) […]

read more
Showing the single result